A Fertile Empire: Andrej Babiš’s Expanding Business Interests and EU Scrutiny
Former Czech Prime Minister Andrej Babiš built his considerable wealth initially through the fertilizer industry. However, a less publicized facet of his business empire has quietly played a role in the births of over 170,000 children across Europe, according to reporting by Politico. This expansion into assisted reproductive technologies, through the network of clinics known as FutureLife, alongside ventures into lingerie, flowers, and other sectors, has raised concerns within the European Union regarding potential conflicts of interest and the opaque flow of EU funds. The complexity of Babiš’s holdings, structured through a network of companies and investment funds, presents a challenge for EU oversight, prompting questions about transparency and accountability.
FutureLife, one of the largest IVF clinic networks in Europe, operates 60 clinics across 16 countries, from the Czech Republic to Spain and Ireland. While Babiš’s name is rarely directly associated with the company, it forms a significant part of his broader commercial portfolio. This portfolio is managed through Hartenberg Holding, a private investment fund co-founded by Babiš and Jozef Janov in 2013, separate from his Agrofert conglomerate, which has been the primary focus of conflict-of-interest debates. The structure allows Babiš to maintain a controlling stake in Hartenberg through SynBiol, a company he fully owns, while distancing himself publicly from its day-to-day operations.
The scale of Hartenberg’s investments, estimated at approximately €600 million (roughly 14.6 billion Czech koruna as of February 2026), extends beyond assisted reproduction to include retail, aviation, and real estate. This diversification, coupled with Babiš’s continued participation in EU negotiations concerning budgets, health regulations, and industrial policy, has fueled anxieties about potential undue influence and the possibility of benefiting from EU subsidies without full transparency. The European Parliament previously adopted a resolution in 2021 condemning Babiš over conflicts of interest involving EU subsidies and companies he founded, but effective oversight remains hampered by the lack of a centralized EU-wide register linking ultimate beneficial owners to EU payments.
Expanding Beyond Reproduction: A Diversified Portfolio
Babiš’s entry into the assisted reproductive technology sector began in 2014 with the acquisition of Reprofit, a pioneering IVF clinic in Brno, Czech Republic. Tradeinfo.cz reports that this initial investment sparked a series of acquisitions, culminating in the creation of FutureLife, which now encompasses over 50 clinics and laboratories across Europe, including locations in Spain, Romania, Germany, the United Kingdom, Slovakia, and the Baltic states. The success of FutureLife is attributed to a combination of high-quality medical care, innovative approaches, and substantial investment capital.
In 2025, Babiš’s group further expanded its reach by entering the Turkish market, marking its most ambitious expansion outside of traditional European territories. Turkey’s growing healthcare sector and increasing popularity as a destination for medical tourism made it an attractive target. iROZHLAS reported that Babiš acquired nine clinics in Turkey and the Balkans, solidifying FutureLife’s position as a leading provider of assisted reproductive services in Europe.
However, FutureLife represents only a portion of Babiš’s diverse business interests. In 2019, Hartenberg acquired a majority stake in Flamengo, a Czech flower chain operating approximately 200 stores. The online lingerie retailer Astratex, now under Babiš’s control, operates localized e-commerce platforms in around ten European markets, generating tens of millions of euros in annual revenue. Further online ventures linked to Babiš sell sporting goods, wool, and textiles. Hartenberg has also invested in urban development and real estate, including a significant early investment in the Císařská vinice project in Prague, a residential development near Ladronka Park.
EU Concerns and the Lack of Transparency
The lack of transparency surrounding Babiš’s business empire has drawn criticism from EU officials. Daniel Freund, a German Green lawmaker, highlighted the difficulty in tracking EU funds potentially flowing to companies associated with Babiš, stating, “We might be giving him money and we don’t even know,” as reported by Politico. Under EU rules, member states are responsible for identifying and reporting conflicts of interest and ensuring transparency in the allocation of EU funds, but the absence of a unified EU-wide registry makes cross-border oversight challenging.
In a move seemingly aimed at addressing conflict-of-interest concerns, Babiš transferred all shares of Agrofert into a private trust fund, RSVP Trust, in the previous week. However, the European Commission continues to investigate potential conflicts of interest. Zuzana Mrázová, the Czech Minister for Local Development, confirmed that her office received a letter from the European Commission regarding Babiš’s potential conflicts of interest and is currently preparing a response. The Commission has acknowledged that it does not maintain a list of companies owned or controlled by Babiš within EU member states, nor does it have an overview of EU funds received by companies linked to him outside of Agrofert.
The responsibility for monitoring conflicts of interest and reporting on the ultimate beneficiaries of EU funds rests with individual member states. The absence of a centralized EU-wide registry hinders effective oversight, making it difficult to track the flow of funds and ensure accountability. This situation underscores the need for greater transparency and coordination in the management of EU finances.
Key Takeaways
- Expanding Business Empire: Andrej Babiš’s business interests extend far beyond fertilizers, encompassing assisted reproductive technologies, retail, and real estate.
- EU Scrutiny: The complexity of Babiš’s holdings and his continued involvement in EU negotiations have raised concerns about potential conflicts of interest.
- Transparency Issues: The lack of a centralized EU-wide registry makes it difficult to track the flow of EU funds to companies associated with Babiš.
- FutureLife’s Growth: FutureLife has become one of the largest IVF clinic networks in Europe, operating in 16 countries.
As of February 2026, the European Commission is awaiting a response from the Czech Ministry for Local Development regarding the concerns raised about potential conflicts of interest. Further developments are expected as the Commission continues its assessment of the situation. The ongoing scrutiny highlights the importance of transparency and accountability in ensuring the integrity of EU funding and decision-making processes. Readers are encouraged to share their thoughts and perspectives on this evolving situation in the comments below.